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Innate and adaptive immunity has evolved complex molecular mechanisms regulating 
immune cell migration to facilitate the dynamic cellular interactions required for its func-
tion involving the chemokines and their receptors. One important chemokine receptor 
in the immune system is represented by CCR7. Together with its ligands CCL19 and 
CCL21, this chemokine receptor controls different arrays of migratory events, both in 
innate and adaptive immunity, including homing of CD56bright NK cells, T cells, and DCs to 
lymphoid compartments, where T cell priming occurs. Only recently, a key role for CCR7 
in promoting CD56dim NK cell migration toward lymphoid tissues has been described. 
Remarkably, this event can influence the shaping and polarization of adaptive T cell 
responses. In this review, we describe recent progress in understanding the mechanisms 
and the site where CD56dim KIR+ NK cells can acquire the capability to migrate toward 
lymph nodes. The emerging significance of this event in clinical transplantation is also 
discussed.
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iNTRODUCTiON
NK cells are effector cells of the innate immune system able to recognize and kill stressed, trans-
formed, or virus-infected cells via a delicate balance of signals transmitted by activating and inhibi-
tory receptors, and to secrete various effector molecules (1–3).
Two main subsets of human NK cells have been identified, according to the cell surface density 
of CD56 and expression of CD16 (FcγRIIIa). The CD56dim CD16bright NK cell subset expresses 
KIR and/or CD94/NKG2A molecules and predominates in peripheral blood (~90% of circulating 
NK cells), while the CD56bright CD16neg/dim NK cells express CD94/NKG2A (but are KIR negative) 
and represent only ~10% of circulating NK cells. CD56dim CD16bright NK cells display potent cyto-
lytic activity and produce cytokines following receptor-mediated stimulation (e.g., engagement 
of activating surface receptors during target cell recognition) (4–6). On the other hand, CD56bright 
CD16neg/dim NK cells produce cytokines including interferon-γ (IFNγ), tumor necrosis factor-α 
(TNFα), and granulocyte–macrophage colony-stimulating factor (GM-CSF) and undergo prolif-
eration following stimulation with pro-inflammatory cytokines. Cytolytic activity is acquired only 
after prolonged cell stimulation (4–6). Notably the CD56bright CD16neg/dim NK cells can undergo dif-
ferentiation into CD56dim CD16bright NK cells. Moreover this subset can undergo further phenotypic 
and functional maturation toward terminally differentiated NK cells (7–10).
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wHAT DeTeRMiNeS NK CeLL SUBSeT 
ReCRUiTMeNT TO DiFFeReNT ORGANS 
DURiNG PHYSiOLOGiCAL AND 
PATHOLOGiCAL CONDiTiONS?
In bone marrow, NK cell precursors undergo a maturation pro-
cess that includes the acquisition of effector functions and the 
expression of chemotactic receptors that will drive their migra-
tion from the bone marrow to different organs through the blood 
stream (11, 12).
The recirculation and the distribution of cells of the immune 
system to the various organs depend primarily on the release of 
particular chemokines by organ-specific cell types (13, 14).
NK cells can respond to a large array of chemokines (13), 
and can be recruited to different district of the body and to 
sites of inflammation (15, 16). The distribution of NK cells is 
subset specific. Indeed, the two main NK cell subsets display 
major functional differences not only for their cytolytic activity 
and modality of cytokine production but also in their homing 
capabilities, as shown by their organ-specific localization (16). 
In particular, the cytolytic CD56dim CD16bright NK cell subset 
expresses CXCR1, CX3CR1, and ChemR23 chemokine receptors; 
therefore, it is mainly recruited to inflamed peripheral tissues. 
In contrast, CD56bright CD16neg/dim NK cells preferentially express 
CCR7 and are primarily attracted by secondary lymphoid organs 
(lymph nodes, tonsils, and spleen) (17–20). These cells also 
express CD62L (L-selectin), which provides important adhesion 
to endothelial surfaces, required for extravasation of CD56bright 
NK cells (21). Accordingly, CD56bright NK cells are 10 times more 
frequent than CD56dim in parafollicular (T-cell) regions of healthy 
(non-inflamed) lymph nodes, where they can be activated by 
T-cell-derived IL-2 (19, 22). Therefore, it is likely that the expres-
sion of the high-affinity IL-2 receptors on CD56bright NK cells may 
promote a cross talk between NK and T cells in these lymphoid 
compartments (19).
It has recently been shown that, in addition to secondary 
lymphoid compartments (SLCs), CD56bright CD16neg/dim NK cells 
populate other normal human tissues. These include uterine 
mucosa, liver, skin, adrenal gland, colorectal, liver, and visceral 
adipose tissues. On the other hand, tissues such as lung, breast, 
and sottocutaneous adipose tissue contain preferentially CD56dim 
CD16bright cells (14, 16, 23).
The specific distribution of the two subsets is mainly reflect-
ing differences in their chemokine receptor repertoires and, as a 
consequence, in their ability to respond to different chemotactic 
factors (14, 16, 23).
Remarkably the localization of the two NK cell subsets can 
change in pathological conditions, e.g., in the presence of tumors 
(16). Thus, in different tumor types, both migration and hom-
ing of NK cells may be altered and even reversed. For example, 
NK cells present in tumor-infiltrated peripheral tissues are often 
enriched in CD56bright CD16neg/dim NK cells (24–26); in contrast, 
an expansion of an unusual subset characterized by a CD56dim 
CD69+ CCR7+ KIR+ phenotype has been detected in tumor-
infiltrated lymph nodes (27). A possible explanation of these 
findings is that, a different pattern of chemokines, released by 
cells of the tumor microenvironment, or the acquisition of differ-
ent/new chemokine receptors by NK cells, may operate an altered 
recruitment of the two NK cell subsets.
Thus, chemokines/chemokine receptors play a critical role in 
the regulation of the distribution of NK cell subpopulations in the 
various tissues, both in normal and the pathological conditions, 
such as inflammatory processes or tumors.
Notably, also organ-specific features, such as the anatomical 
structure, the type of cells present in the tissue, the soluble factors 
released, and the different interactions that NK cells can establish 
with different cell types, may considerably influence their homing 
capability.
wHAT CONDiTiONS DeTeRMiNe NK 
CeLL ACTivATiON iN iNFLAMeD 
TiSSUeS?
As illustrated above, in the course of pathological conditions, 
such as inflammation, viral infection, and tumor growth, NK 
cells are rapidly recruited from peripheral blood into injured 
tissues, thanks to the interplay between chemokines and their 
receptors (20, 28–31).
NK cells, once they reach inflammatory sites, need to be 
activated in order to perform their functional activities. NK cell 
activation can occur through different types of signals. These 
include signals delivered by several activating NK receptors (32), 
upon recognition of specific ligands expressed on tumor cells, or 
signals generated in response to stimulation via toll-like recep-
tors (TLR) that are constitutively expressed by NK cells and allow 
their responses to products of viral or bacterial origin (3, 33, 34). 
In addition, the activation of NK cells can occur through various 
soluble signals, including different cytokines that are provided by 
other cell types. Indeed, although NK cells can directly recognize 
cells infected by viruses and/or transformed cells, many recent 
studies revealed that the microenvironment and the interaction 
with other cells of the immune system, in particular with DCs, 
may considerably contribute to ensure an optimal priming of NK 
cells. For example, the production of cytokines (such as IL-12) 
by activated DCs improves NK cell proliferation, production of 
IFNγ, and antitumor cytotoxic activity (35).
In addition, a full NK cell activation allows the establishment 
of important processes, such as the mechanism of NK-mediated 
“editing” of DCs (28), which would play a crucial role in con-
trolling the induction of appropriate antigen-specific adaptive 
immune responses (36, 37). In particular, activated NK cells 
appear to contribute to the quality control of immature DCs 
(iDCs) undergoing maturation by selecting DCs most fitting to 
optimal antigen presentation (36, 38). This process is thought 
to be crucial for the subsequent DC migration to SLCs and 
priming of naïve T lymphocytes toward Type 1 (Th1) immune 
responses.
In this context, it has to be considered that the exposure of 
NK cells to type II cytokines, such as IL-4 (35), released by other 
cells of the innate immune system in certain inflammatory 
microenvironments may result in low levels of cytotoxicity 
against tumor cells. Importantly, NK cells would become unable 
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to kill iDCs and to release IFNγ and TNFα. This results in 
the failure of an efficient “editing” process and in the genera-
tion of Th0 cell leading to non polarized T cell responses in 
lymph nodes that compromise downstream antigen-specific, 
Th1-mediated immune responses (35). On the other hand, 
IL-4 by driving a type II immune response may be important 
for the eradication of particular pathogens. The absence of 
NK cells driving a Th1 response, in this circumstance, may 
be optimal for an efficient immune response to that particular 
pathogen (39).
Other studies suggest that NK cells may play not only a ben-
eficial regulatory role in shaping adaptive immune responses 
but also an inhibition of the adaptive immune cells (e.g., T and 
B cells), by killing both antigen-presenting cells (APCs) and 
antigen-specific T cells and by producing anti-inflammatory 
cytokines, such as IL-10. These events can shape the overall 
immune response against certain pathogens, which can have 
consequences for disease pathogenesis, and infection outcome. 
Continued evaluation of the specific context-dependent roles 
of NK cells in human infection will be necessary to guide 
attempts to modulate NK cells in therapy or prevention of 
infection (40).
Thus, depending on the nature of the pathogens responsible 
for the invasion of a given tissue and, as a consequence, on the 
cytokine microenvironment created during the early stages of an 
inflammatory response, NK cells may differentially contribute to 
the quality and magnitude of both innate and adaptive immune 
responses (1, 35, 41).
HOw DO THe PHeNOTYPiC PROPeRTieS 
(AND THe eFFeCTOR FUNCTiONS) OF NK 
CeLLS CHANGe FOLLOwiNG 
ReCRUiTMeNT TO iNFLAMeD 
PeRiPHeRAL TiSSUeS?
According to the data reported in the previous paragraphs, 
there is clear evidence that CD56dim CD16+ NK cells, which 
have been recruited into inflamed tissues, in the presence of 
pro-inflammatory stimuli favoring their interaction with DCs 
(28, 31, 42–44) may usually influence naïve T cell priming, for 
instance by the “DC editing program.” This mechanism may take 
place in the periphery and, at least in some instances, does not 
require the recruitment of tissue-activated NK cells into lymph 
nodes (35, 41, 45).
On the other hand, the inflammatory microenvironment and 
the interactions established with other cells at the inflammatory 
sites may also affect both phenotypic and homing properties 
of NK cells by generating altered NK cell subsets. For example, 
there is evidence that, during an immune response, the highly 
cytotoxic CD56dim KIR+ (as well as CD56dim KIR− NKG2A+) NK 
cells, that, different from CD56bright NK cells are CCR7 negative, 
could be directed from the peripheral (non-lymphoid tissues) 
toward inflamed lymph nodes. These represent a crucial site for 
NK cell-mediated immunosurveillance against tumor metastases 
and the control of viral infections and also contribute to priming 
of adaptive immune responses (27, 41, 46).
In this context, it has been demonstrated that NK cells exposed 
to a microenvironment rich of IL-18 may de novo express CCR7 
and, thus, acquire the ability to respond to the lymph node 
chemokines CCL19 and CCL21 (47).
IL-18 may be released by APCs in an inflammatory microen-
vironment triggered by pathogens. In this regard, it has recently 
been demonstrated that M0 and M2 macrophages express a 
membrane form of IL-18 (mIL-18), which is released in the 
course of polarization to M1, induced by bacterial stimuli (LPS 
or BCG). IL-18 induces NK cells to release large amounts of IFNγ 
and plays a pivotal role in the expression on their surface of CCR7 
receptor (47, 48) (Figure 1A).
The acquisition of CCR7 provides CD56dim KIR+ NK cells with 
the potential to reach lymph nodes where they can interact with 
DCs and T cells and regulate T cell responses (41, 47, 49). On the 
other hand, the expression of CCR7 in response to IL-18 can occur 
only in resting NK cells, because cytokine-mediated priming of 
NK cells induces their activation and a marked downregulation of 
IL-18Rα expression (50, 51). In light of these data, it is conceivable 
that other mechanisms may contribute to the acquisition of CCR7 
by “activated” CD56dim NK cells. Indeed, recent data revealed 
that an unexpected crosstalk between NK cells and other cells 
present in the inflamed niche environment (tumor/infected cells 
or other immune cells, including DCs and T cells) leads to the 
de novo surface expression of CCR7 by CD56dim KIR+ NK cells in 
an IL-18-independent manner (51–54) (Figures 1B,C).
The acquisition of CCR7 by these NK cells requires direct 
cell-to-cell contact, is detectable within few minutes, and is due 
to receptor uptake from CCR7+ cells. This mechanism is termed 
“trogocytosis” and is distinct from other mechanisms of intercel-
lular exchanges, such as nanotubes and exosomes (55–58). For 
example, interaction between NK cells and mature DCs (mDCs) 
that express surface CCR7 could induce its expression on NK 
cells (52).
An important aspect is that the acquisition of CCR7 is 
promoted by non-HLA-specific activating receptors (including 
NKp46), but, it is negatively regulated by the interaction between 
inhibitory KIR receptors expressed by NK cells (“acceptor”) and 
HLA class I molecules expressed by CCR7+ cells (“donor”). In 
particular, in the course of infection in a self-environment, KIR+ 
NK cells can acquire CCR7 only when they interact with HLA 
class I negative CCR7+ cells (e.g., target cells that have undergone 
tumor transformation or viral infection) (Figure  1B). On the 
contrary, in an allogeneic setting characterized by KIR/HLA class 
I mismatch, KIR+ NK cells can acquire CCR7 following interac-
tion with any CCR7+ cell, including those expressing high levels 
of HLA class I, such as mDCs (Figure 1C).
This condition is reproduced during KIR-mismatched haploi-
dentical hematopoietic stem cell transplantation (haplo-HSCT) 
to cure high-risk leukemias (46, 59). Importantly, these events 
have been recently reproduced and confirmed in vivo in a mouse 
model (53).
Thus, the de novo CCR7 expression renders CD56dim KIR+ 
NK cells able to migrate into the SLCs in response to CCL19 
and CCL21 chemokines (47, 52, 54). In this compartment, NK 
cells release IFNγ (directly promoting the development of Th1 
responses) and exert their cytotoxic activity against different 
FiGURe 1 | in this figure, it is shown that CD56dim KiR+ NK cells, after recruitment from blood into inflamed peripheral tissues in response to 
chemokine gradients, may de novo express CCR7, a chemokine receptor able to confer immune cells with the ability to migrate to lymph nodes.  
(Continued)
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This event may occur in a microenvironment rich in IL-18, a pro-inflammatory cytokine released by M0 macrophages during differentiation toward M1 following 
activation. This de novo expression can be induced only on a fraction of NK cells characterized by the expression of the IL-18Rα (resting NK cells), whereas it 
cannot be induced on activated NK cells that express little IL-18Rα (A). Otherwise, the expression of CCR7 on CD56dim NK cells can be induced by a mechanism of 
trogocytosis on either resting or activated NK cells, regardless of their level of IL-18Rα expression. This mechanism is finely controlled by the specific interaction 
between KIRs on NK cells and HLA class I molecules on CCR7+ cells. In particular, inhibitory KIRs block this transfer, whereas some activating KIRs are able to 
strongly promote the CCR7 acquisition by NK cells. This means that in an autologous setting, NK cells may acquire CCR7 only by interacting with HLA-I negative 
CCR7+ cells, such as transformed cells (B). In contrast, in an allogeneic setting, as in haplo-HSCT, characterized by KIR/HLA class I mismatch, KIR+ alloreactive 
NK cells can express CCR7 when they interact with allogeneic CCR7+ mDCs (C).
FiGURe 1 | Continued
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types of targets, including tumor cells or (in an allogeneic system 
such as in transplantation) other target cells including patient’s 
DCs (46).
In line with these data, Martin-Fontecha et  al. showed that 
murine NK cells can be recruited to lymph nodes in a CXCR3-
dependent manner by the injection of mDCs and that these 
recruitment correlated with the induction of Th1 responses (60). 
The induction of IFNγ release by NK cells migrated into lymph 
nodes appears to depend on direct interactions with DCs that 
release IL-12 and provide IL-15 by trans-presentation (61).
Very recently, it has been shown that NK cells can be geneti-
cally reprogramed efficiently using a electroporation method 
with mRNA coding for the chemokine receptor CCR7, in order 
to induce the expression of this chemokine receptor on their 
surface and the consequent NK cell migration toward the lymph 
node-associated chemokine CCL19 (62).
DOeS CCR7+ eXPReSSiON ON 
ALLOReACTive KiR+ NK CeLLS PLAYS 
A ROLe iN TRANSPLANTATiON?
Alloreactivity in haploidentical haplo-HSCT is operating 
through the mechanism of “missing self ” recognition, provided 
that the donor expresses a given inhibitory KIR, whose ligand is 
missing in the recipient’s HLA genotype. This combination will 
lead to a KIR/KIR–ligand mismatch in graft-versus-host (GvH) 
direction (63–67). In particular, it has been shown that, in T-cell 
depleted haplo-HSCT, “alloreactive” NK cells kill KIR–ligand 
mismatched leukemic blasts (graft versus leukemia, GvL), thus 
contributing to eradication of high-risk acute myeloid or lym-
phoid leukemias. It is of note that, in this transplantation setting, 
all cases would be at risk of T cell-mediated alloreactivity both 
in the HvG and in the GvH direction. However, patients trans-
planted from an NK “alloreactive donor” benefit from higher 
rates of engraftment and reduced incidence of graft-versus-host 
disease (GvHD) (68–71).
Such low rate of GvHD would be consequent to the inefficient 
priming of alloreactive donor T cells (reconstituted from donor 
CD34+ HSC precursors) due to the NK cell-mediated killing of 
recipient’s APCs (68). Furthermore, NK cells are able to eliminate 
residual patient’s T cells, thus preventing HvG reactions and 
thereby promoting engraftment. In agreement with this concept, 
in vitro studies showed that alloreactive NK cell clones are able to 
kill not only leukemic blasts (71) but also allogeneic mDCs and 
T cell blasts (59, 72), while sparing other tissues that are com-
mon targets for T-cell-mediated GvHD (70). Although some of 
these target cells might be killed within peripheral tissues, it is 
conceivable that the elimination of patient’s DCs by alloreactive 
NK cells occurs primarily within lymph nodes, thus preventing 
GvH reactions. Indeed, it is mainly at these sites that patient’s DCs 
would prime donor’s allospecific naïve T cells.
However, since KIR+ NK cells do not express CCR7, it was 
difficult to explain how donor’s KIR-mismatched NK cells could 
get in close proximity with recipient DCs and kill them within 
lymph nodes. In this context, our findings on trogocytosis of 
CCR7 have provided a possible explanation for the mechanism 
by which KIR-mismatched NK cells can acquire CCR7, migrate 
to lymph nodes, and kill recipient’s DC, thus preventing GvH 
responses in this compartment (52).
Recent evidence revealed that the expression of activat-
ing KIRs, in particular KIR2DS1 (specific for HLA-C2) could 
improve the clinical outcome in haplo-HSCT. It is interesting 
that the expression of KIR2DS1 can induce alloreactivity by an 
otherwise non-alloreactive subset of NK cells expressing NKG2A. 
Thus, in appropriate donor/recipient pairs, the expression of 
KIR2DS1 can considerably increase the fraction of alloreactive 
NK cells (71, 72). In light of these data, we could demonstrate 
that the activating KIR KIR2DS1 represented an advantage for 
CCR7− NK cells favoring the acquisition of this receptor from 
HLA-C2+ CCR7+ cells. In particular, we showed that NK cell, 
triggered by this receptor in NK cell clones expressing the 
KIR2DS1+/NKG2A+ phenotype (isolated from C1+ donors), 
could by-pass almost completely the inhibition mediated by 
NKG2A, thus making NKG2A+ cells (which usually are not 
alloreactive) capable of killing allogeneic target cells expressing 
HLA-C2+ and HLA-E. Remarkably, this interaction results also 
in the capture of CCR7 from CCR7+ cells that express HLA-
C2, including EBV-transformed B cell lines as well as mDCs 
or T blasts derived from C2+ donors. We also showed that the 
ability to migrate in response to CCL19/21 NK cell was directly 
proportional to the level of expression of CCR7 acquired after 
coculture with CCR7+ cells (54). Hence, the acquisition of CCR7 
on CD56dim KIR+ NK cells is negatively regulated by inhibitory 
KIRs, but is strongly favored by positive signals delivered by 
activating KIR (52, 54, 59). In line with these results, it has been 
shown that also the KIR2DS4-activating receptor (73, 74) may 
induce the uptake of CCR7 by some KIR2DS4+ NKG2A+ NK 
cell clones upon interaction with CCR7+ target cells expressing 
appropriate HLA-C alleles (51).
In conclusion, it is conceivable that the migration of CD56dim 
KIR+ NK cells to lymph nodes may play an important role not 
only in the mechanism of Th1 polarization in adaptive immune 
responses (through the release of IFNγ and the mechanism of 
FiGURe 2 | in KiR-mismatched haplo-HSCT, the late appearance of alloreactive (KiR+) NK cells (6–8 weeks after transplant) may result in a delayed 
anti-leukemia and antiviral infection effect. In order to prevent these risks, a promising approach has been proposed consisting in the infusion of manipulated 
NK cells at short time intervals after HSCT. In particular, trogocytosis could be used as a tool to rapidly and transiently modify the migratory properties of donor-
derived alloreactive NK cells by inducing CCR7 expression on their surface. These alloreactive NK cells, infused during the time required for the maturation of NK 
cells from HSC, may play a relevant role in preventing leukemic relapse (GvL activity), GvH/HvG reactions (by killing patient’s DCs/Tcells), and in controlling infections. 
After this period, mature alloreactive NK cells generated from HSC acquire CCR7 directly (in vivo) from patient’s CCR7+ cells, including mDC and T cell blasts.
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DC “editing”) but also in the prevention of GvHD and HvGD in 
haplo-HSCT.
ARe THeRe POTeNTiAL CLiNiCAL 
APPLiCATiON SUGGeSTeD BY 
THeSe FiNDiNGS?
The data described further support the concept that alloreactive 
NK cells, appropriately selected according to their phenotypic and 
functional characteristics, may play a central role in haplo-HSCT, 
by preventing leukemia relapses and improving engraftment 
by killing leukemia blasts and host APCs, which are known to 
initiate T cell-mediated GvHD (Figure 2). Notably, in the haplo-
HSCT setting, the differentiation of KIR+ alloreactive NK cells 
from CD34+ HSC precursors may require 6–8 weeks. Therefore, 
their anti-leukemia effect would occur only after this time period. 
In case of infections or highly proliferating residual leukemia 
blasts, this delay may represent a major problem, resulting in 
leukemia relapses. In addition, in haplo-HSCT patients, due to 
the extensive T-cell depletion, required to prevent GvHD, there 
is an increased risk of life-threatening infections. With the aim 
to improve posttransplantation immune reconstitution, several 
immunotherapeutic approaches have been applied. For example, 
mature donor alloreactive NK cells may be infused at transplanta-
tion together with HSC and/or at short time intervals after HSCT. 
These NK cells may rapidly kill leukemic cells, thus anticipating 
the effect of alloreactive NK cells generated from transplanted 
HSC (75–77).
Another approach that could improve the efficiency of allore-
active NK cells would be to exploit trogocytosis as a tool to rapidly 
(and transiently) modify lymphocytes, for adoptive immuno-
therapy applications (52, 54). For example, pre-incubation of 
KIR+ NK cells (from an alloreactive donor) with CCR7+ HLA 
7Pesce et al. CCR7+ Alloreactive NK Cells
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class I-deficient cells, before their adoptive transfer to the patient, 
would allow CCR7+ alloreactive NK cells to be rapidly recruited 
to lymph nodes and to eliminate the leukemia cells residual after 
conditioning and patient’s DC/T cells (78) (Figure 2). Importantly, 
in these immunosuppressed patients, CCR7+ KIR+ NK cells could 
also provide a rapid and more efficient line of defense against 
life-threatening infections (Figure 2).
In this context, CCR7 acquired by NK cells via trogocytosis has 
been shown to enhance their lymph node homing upon adoptive 
transfer to athymic nude mice, contributing to eliminate lymph 
node tumor metastases (53).
Trogocytosis may involve several cell surface molecules and 
different cell types, including T and B lymphocytes, NK cells, DCs, 
and tumor cells. It has been proposed that the formation of the 
immune synapse for capturing target cell membrane fragments 
by NK cells may be promoted by the interaction of NK receptors 
with their specific ligands. During this process several molecules 
(included in the immune synapse?) can be transferred from one 
cell to another. For example, upon coculture with the CCR7+ 221 
cell line, NK cells may acquire, together with CCR7, also CD19 
and CD86 (a marker commonly used to assess trogocytosis) (54).
Another interesting possible approach is based on the use 
of anti-KIR mAbs (their use is now in phase II clinical trials 
in patients with acute myeloid leukemia or multiple myeloma) 
(79–83). By blocking inhibitory KIRs, these mAbs, are able to 
confer alloreactivity to any KIR-2D+ NK cell (in individuals 
expressing HLA-specific activating KIRs, such as KIR2DS1, it is 
possible that the use of anti-KIR mAbs may partially modulate 
the function of an NK cell subset expressing this receptor) 
(52, 54). Notably, in this setting, all anti-KIR-treated NK cells 
of a given patient become capable of capturing CCR7 by any 
autologous CCR7+ cell soon after infusion in the patient. These 
“pseudo-alloreactive” NK cells could be rapidly routed toward 
lymph nodes, where they could carry out their functions.
CONCLUSiON
The cross talk occurring between NK cells and DCs further sup-
ports the concept that NK cells play a critical role in the initiation 
and regulation of both innate and adaptive immune responses. 
These cellular interactions allow the establishment of important 
processes crucial for shaping of adaptive immunity: (a) the “DC 
editing program” is a process resulting in the selection of DCs 
with optimal antigen-presenting properties allowing appropriate 
Th1 responses protective against tumors and infections; (b) the 
acquisition of CCR7 expression by human KIR+ NK cells allows 
mature cytolytic NK cells to migrate to lymph nodes and exert 
antitumor and antiviral activity. Moreover, at these sites, NK cells 
may modulate Th1 polarization. In addition, in the haplo-HSCT 
transplantation setting “alloreactive” NK cells, migrated to lymph 
nodes, can mediate important anti-GvH and anti-HvG responses 
by killing recipient’s allogeneic cells, including lymph node DCs 
and T cell blasts.
As illustrated in this review, CCR7 expression by KIR+ cytolytic 
NK cells is based on the capture of this chemokine receptor from 
allogeneic CCR7+ cells by a mechanism termed trogocytosis. 
This event is induced by activating KIRs, including KIR2DS1 and 
KIR2DS4, while it is negatively regulated by inhibitory KIRs and 
NKG2A. Thus, selection of appropriate donor/recipient pairs may 
greatly expand the contingent of alloreactive NK cells migrating 
to lymph nodes in HSCT, by increasing the effectiveness of 
alloreactive NK cells and the positive outcome of transplantation.
In addition to various protocols of chemotherapy and 
radiotherapy, fundamental progress in fighting cancer have been 
recently obtained with immunotherapy, thanks to the use of 
anti-immune checkpoints monoclonal antibodies, such as anti-
CTLA4 and anti-PD-1, that are capable of reversing the function 
of otherwise exhausted tumor-specific T lymphocytes (84–86). 
Importantly, similar novel strategies now can be used also to 
manipulate NK cell function by the use of antibodies targeting 
their major inhibitory checkpoints, such as anti-KIR (79, 82), 
anti-NKG2A (87), and anti-PD-1 (86). In addition, novel means 
to optimize NK cell traffic to crucial sites (e.g., CCR7 acquisition 
and homing to lymph nodes) could be applied to treatment of 
different diseases besides tumors. These include viral infections 
and autoimmune diseases. In conclusion, a promising approach 
to improve the cure of life-threatening diseases may be based on 
“reshaping” NK cell phenotypic and functional properties.
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